A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

نویسندگان

  • Charmi A. Patel
  • Robert A. Bailey
  • Ujjwala Vijapurkar
  • Gary Meininger
  • Lawrence Blonde
چکیده

BACKGROUND The randomized, double-blind CANTATA-SU (CANagliflozin Treatment And Trial Analysis Sulfonyl Urea) clinical trial compared the use of canagliflozin (100 mg or 300 mg) and maximally tolerated glimepiride (6-8 mg) over 104 weeks as add-on therapy for patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Compared with glimepiride, canagliflozin use was associated with durable reductions in glycated hemoglobin (A1C), blood pressure (BP), and body weight. The aim of this post-hoc analysis of the CANTATA-SU trial was to assess the comparative efficacy of canagliflozin and glimepiride in the attainment of recently updated diabetes-related quality measures (QMs) for up to 104 weeks of treatment. METHODS This post-hoc analysis evaluated the proportions of patients achieving individual diabetes-related QMs using data from the randomized, double-blind, Phase 3 CANTATA-SU trial. Change in A1C from baseline, and proportions of the study population achieving QMs: A1C <7.0 %, <8.0 %, and >9.0 % were assessed. Secondary endpoints included change in BP from baseline, and the proportions of the study population achieving QMs related to BP and body weight. RESULTS The proportions of patients in the canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride groups meeting criteria for all QMs were similar at baseline. At 52 and 104 weeks of treatment, canagliflozin 100 mg and canagliflozin 300 mg provided better or similar reductions in A1C from baseline and achievement of glycemic control QMs compared with glimepiride. At 52 and 104 weeks of treatment, the attainment of QMs related to reductions in body weight and BP all favored canagliflozin compared with glimepiride. Canagliflozin was associated with lower incidence of documented hypoglycemia and severe hypoglycemia compared with glimepiride. CONCLUSIONS Using the recently adjusted and currently accepted diabetes-related QMs, this analysis observed superior glycemic control with canagliflozin compared with maximally tolerated glimepiride in patients with T2DM who were previously poorly controlled on metformin monotherapy. Compared with maximally tolerated glimepiride, canagliflozin resulted in better achievement of diabetes-related QMs related to weight loss and BP, and was associated with lower incidences of hypoglycemic events. TRIAL REGISTRATION Clinical trial registry name: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride. CLINICAL TRIAL REGISTRATION NUMBER NCT00968812 , registered August 28, 2009.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

OBJECTIVE Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in a broad range of patients with T2DM. This post hoc analysis assessed the effects of canagliflozin...

متن کامل

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates

AIMS Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates. METHODS This post hoc analysis evaluated patients with T2DM using pooled data from fo...

متن کامل

The effect of twelve weeks of combined exercise with Canagliflozin on the development of insulin resistance factors in type 2 diabetic men

Introduction: The balance between physical activity, medication, and daily food intake helps to regulate blood sugar in people with type 2 diabetes. The aim of this study was to investigate the effect of twelve weeks of combined exercise with Canagliflozin on the development of insulin resistance factors in type 2 diabetic men. Materials and Methods: In this quasi-experimental study, 44 men...

متن کامل

THE EFFECT OF COMBINED TRAINING WITH CANAGLIFLOZIN ON SOME HEPATOKINES IN TYPE 2 DIABETIC MEN

Background: The hepatokines are now considered potential targets for the treatment of type 2 diabetes disorders. The aim of this study was to investigate the effect of 12 weeks combined training with Canagliflozin on some hepatokines in type 2 diabetic men. Methods: In this quasi-experimental study, 44 men with type 2 diabetes (Mean age 33.2 ± 4.5 years, body mass index 27.3±3.0) from Tehran c...

متن کامل

The effect of twelve weeks of combined training with and without canagliflozin consumption on fetuin A and fetuin B in type 2 diabetic men

Introduction: Cardiovascular disease, diabetes, and fatty liver are now considered the major causes of mortality in developing countries. The present study investigates the effect of twelve weeks of combined training with and without canagliflozin consumption on fetuin-A and fetuin B in type 2 diabetic men. Materials and Methods: Forty- four men (25-40 years ) who had type two diabitiac were r...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 16  شماره 

صفحات  -

تاریخ انتشار 2016